They reidentified four candidate biomarkers—α1 antitrypsin (AAT), α‐2‐macroglobulin (A2Macro), ApoE, and complement C3—that showed a significant association with AD‐related phenotypes. This evidence concerns the gene C3 and Alzheimer disease.